1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Otilimab Failure Is A Blow For GSK’s Pipeline, With More Tests To Come

Arthritis Drug Was Blockbuster Candidate

 
• By Andrew McConaghie

GSK is abandoning one of its new drug prospects after it failed in hard-to-treat rheumatoid arthritis patients at Phase III, raising the stakes for more key readouts due shortly.

GSK Stevenage
GSK is aiming to generate around $23bn in revenues from new products, but has had mixed results so far this year. • Source: GSK

GSK’s late-stage pipeline has been dealt a blow by the failure of its rheumatoid arthritis candidate, otilimab, in a Phase III program.

The company has revealed that otilimab, a novel monoclonal antibody treatment for rheumatoid arthritis (RA), met its primary endpoint in only two out of three parallel ContRAst Phase III studies in difficult-to-treat patients

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 
• By Jessica Merrill

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies